Clinical trials: Enoxaparin, completed
Venous Thromboembolism, Pulmonary Embolism
A Different Approach to Preventing Thrombosis
The purpose of this study is to perform a pragmatic randomized controlled trial to compare the use of low molecular weight heparin (LMWH, lovenox, enoxaparin) versus acetylsalicylic acid (ASA) for venous thromboembolism (VTE)…
- Trial name
- ADAPT (NCT02774265)
- Testing
- VTE prophylaxis with Enoxaparin 30mg BID, VTE prophylaxis with Aspirin 81mg BID
- Where
- United States
- Volunteers
- 329 people
- Sponsor
- University of Maryland, Baltimore
Androgenetic Alopecia, Hair Loss
Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study
This is a comparative retrospective study of the efficacy of platelet-rich plasma injections and injections with commercial products advertised to promote hair regrowth for patients with androgenetic alopecia.
- Conditions
- Androgenetic Alopecia, Hair Loss, Alopecia
- Trial name
- NCT05129800
- Testing
- Platelet-rich plasma, Mesotherapy
- Volunteers
- 72 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Kidney Disease
Safety Evaluation of Use Sodic Enoxaparin
The purpose of this study was to evaluate safety, not inferiority clinical and pharmacodynamic profile of the drug Enoxaparin Sodium produced by laboratory Blausiegel when compared with Clexane product, produced by Laboratory…
- Trial name
- Enoxaparin (NCT00673426)
- Testing
- Enoxaparin sodic
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Azidus Brasil
Total Knee Replacement
Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement
To evaluate influence of therapy on the following efficacy and safety parameters in different TeaRx dose groups and Enoxaparin group: Total venous thromboembolic events (VTE), which includes confirmed deep venous thrombosis…
- Trial name
- NCT03088358
- Testing
- TeaRx, Enoxaparin
- Where
- 8 sites in Russia
- Volunteers
- 200 people
- Sponsor
- TeaRx LLC
Fetal Growth Retardation
Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction
Intrauterine growth restriction (IUGR) is correlated to an abnormal placenta development, with an alteration of the maternal-fetal circulation, coagulation troubles, and apparition of placental infarcts.
- Trial name
- GROWTH (NCT02672566)
- Testing
- Enoxaparin, Usual care
- Where
- 8 sites in France
- Volunteers
- 82 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Venous Thrombosis, Neoplasms
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
The goal of the pilot study is to determine if a multicenter prospective cohort study of cancer patients with blood clots associated with catheters is feasible.
- Trial name
- NCT01999179
- Testing
- Heparin, Low-Molecular-Weight, or direct oral anticoagulants
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Medical College of Wisconsin
Gastrointestinal Neoplasms, Thromboembolic Event
Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®
Prospective, monocentric, randomized, parallel group, rater-blinded study using two formulations of Enoxaparin sodium (ENOXA® vs LOVENOX®) to compare the thromboembolic events (symptomatic and asymptomatic) in patients undergoing…
- Trial name
- ENOXACARE (NCT02444572)
- Testing
- Enoxaparin 4000 IU
- Where
- Tunisia
- Volunteers
- 168 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Covid19
Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients
The purpose of this study is to determine whether a higher dose of low molecular weight heparin (enoxaparin 40 mg b.i.d.) is superior than the standard prophylaxis dose (enoxaparin 40 mg o.d.) in reducing thromboembolic events in…
- Trial name
- X-Covid 19 (NCT04366960)
- Testing
- Enoxaparin
- Where
- Italy
- Volunteers
- 189 people
- Sponsor
- Niguarda Hospital
Enoxaparin
Pharmacodynamic Equivalence of Ovine Enoxaparin to Lovenox®
This study is designed as a randomized, open-label, 2-way cross-over, single dose study with at least 7 days wash-out period. The objective of this study is to demonstrate the pharmacodynamic / pharmacokinetic equivalence of…
- Trial name
- NCT04402762
- Testing
- Ovine Enoxaparin, Enoxaparin Prefilled Syringe [Lovenox]
- Where
- Indonesia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Gastric Cancer, Gastroesophageal Cancer
Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
Due to evidence available both in terms of efficacy and safety of low molecular weight heparin, its use for the prevention of thromboembolic disease in cancer patients undergoing surgical intervention, and its extended use in…
- Trial name
- GASTRANOX (NCT00718354)
- Testing
- Enoxaparin, Standard Chemotherapy
- Where
- 15 sites in India
- Volunteers
- 740 people
- Sponsor
- Thrombosis Research Institute
Covid19
Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)
This study is a multicenter, randomized trial to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low molecular weight heparin (LMWH) (Lovenox) in…
- Trial name
- XACT (NCT04640181)
- Testing
- Enoxaparin, Rivaroxaban
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- St. David's HealthCare
Acute Coronary Syndrome
Enoxaparin Bioequivalence Study in Acute Coronary Syndrome Patients
Because of their anti-Xa and ease of administration activity, the Low molecular weight heparin represent an attractive alternative to the unfractionated heparin.
- Trial name
- Enoxaparine (NCT04552067)
- Testing
- Lovenox, Enoxaparin
- Where
- Tunisia
- Volunteers
- 172 people
- Sponsor
- University of Monastir
Arthroplasty, Replacement, Knee, Thromboembolism
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
To determine the comparative efficacy and safety of two different doses (75mg day 1 followed by 150 mg day 2-completion, and 110 mg day 1 followed by 220 mg day 2-completion) of dabigatran administered orally (capsules), compared…
- Trial name
- NCT00152971
- Testing
- Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion
- Where
- 94 sites in United States, Canada and 2 more
- Volunteers
- 2,615 people
- Sponsor
- Boehringer Ingelheim
Coagulation Disorder
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin
A single centre, open-label study to assess the effects of VMX-C001 in combination with an oral FXa DOAC on the efficacy of Unfractionated Heparin (UFH) and of VMX-C001 alone on the efficacy of Low Molecular Weight Heparin (LMWH)…
- Trial name
- NCT06517563
- Testing
- VMX-C001, Rivaroxaban, UFH
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Habitual Abortion
Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion
1 % of all pregnancies end in habitual/recurrent abortion. In about half of women with habitual abortions (HAB) hereditary or acquired (antiphospholipid antibodies) thrombophilia are observed.
- Trial name
- HABENOX (NCT00959621)
- Testing
- Aspirin, Klexane, Klexane and ASA
- Where
- Finland
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Helsinki
Coronary Disease
Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease
Anticoagulation with heparin is indicated in several situations, such as acute coronary disease (in combination with antiplatelet therapy) for the prevention and treatment of venous thromboembolism and situations with high risk…
- Trial name
- NCT02389582
- Testing
- Dabigatran, Enoxaparin
- Where
- Brazil
- Volunteers
- 29 people
- Sponsor
- University of Sao Paulo General Hospital
Deep Vein Thrombosis (DVT)
Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery
The goal of this clinical trial is to see if a nurse-led program (early movement, leg-sleeve squeezes, and blood tests) can prevent dangerous leg blood clots in adults who have just had brain or spine surgery.
- Trial name
- NCT07330661
- Testing
- nurse-led program (early movement, leg-sleeve squeezes, and blood tests)
- Where
- China
- Volunteers
- 1,286 people
- Sponsor
- West China Hospital
Pancreatic Cancer
Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer
Venous thromboembolic events are considered to be a prognostic negative factor and small studies showed astonishing survival advantages using heparin as prophylactic treatment to prevent venous thromboembolic events.
- Trial name
- NCT01945879
- Testing
- Enoxaparine
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- CONKO-Studiengruppe
Thromboembolism
Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
Evaluate the safety and tolerability of escalating oral doses of YM150 in patients undergoing elective primary total knee replacement surgery
- Trial name
- PEARL-1 (NCT00408239)
- Testing
- YM150, enoxaparin
- Where
- 19 sites in Indonesia, Japan and 6 more
- Volunteers
- 367 people
- Sponsor
- Astellas Pharma Inc
Venous Thromboembolism
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
The study drug, BAY59-7939, is a new drug currently being tested in the prevention of VTE. It directly inhibits factor Xa, a blood component in the pathway which leads to coagulation (clotting of blood cells).
- Trial name
- NCT00402467
- Testing
- Rivaroxaban (BAY59-7939), Rivaroxaban, (BAY59-7939), Enoxaparine
- Where
- 36 sites in United States, Canada
- Volunteers
- 613 people
- Sponsor
- Bayer